Researchers: ‘Smart’ contact lenses may one day enable wireless glaucoma detection
May 13th 2024A team of Chinese researchers have been working on a way to continuously and more comfortably detect these tiny fluctuations in pressure, such as contact lenses that transmit signals to receptor glasses.
Read More
ARVO 2024: Predicting 3-year myopia control efficacy from 1-year data
May 11th 2024At this year's ARVO meeting in Seattle, Washington, the Eye Care Network spoke with Noel Brennan, MScOptom, PhD. The clinical research fellow at Johnson and Johnson shared highlights from his presentation on myopia control and predictive modeling.
Read More
At this year's ARVO meeting in Seattle, Washington, Dolly Chang, MD, PhD, presented data on the early fluid reduction in patients with diabetic macular edema, and how that correlates with 1-year outcome with a deep learning-based retina segmentation tool using the Phase 2 BOULEVARD trial.
Read More
ARVO 2024: Impact of switching when using an aflibercept biosimilar
May 9th 2024SriniVas R Sadda, MD, presented "Post Hoc Analysis of a Phase 3 Trial on SB15 (Proposed Aflibercept Biosimilar): Assessment on Pre-to-Post Switching Efficacy and Safety in Neovascular Age-related Macular Degeneration."
Read More
ARVO 2024: A study on multi-ingredient oral supplement for dry eye symptoms and tear volume
May 7th 2024Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington, from May 5 to May 9, on a multi-ingredient oral supplement on dry eye symptoms and tear volume.
Read More
ARVO 2024: Post-hoc analysis of GOBI and MOJAVE trials for perfluorohexyloctane
May 7th 2024John Sheppard, MD, MSc, FACs, sat down to discuss post-hoc analysis of 2 FDA registration trials for perfluorohexyloctane, GOBI and MOJAVE, at this year's ARVO meeting held in Seattle, Washington, from May 5 to May 9.
Read More
ARVO 2024: Clinical evaluation of a novel lipid-containing eye drop
May 7th 2024Eric Donnenfeld, MD, sat down to discuss presentations on the novel new artificial tear, Blink Triple Care, about its efficacy in a non-controlled trial as well as comparison to the Classic Blink at this year's ARVO meeting held in Seattle, Washington, from May 5 to May 9.
Read More
ARVO 2024: Researchers detail novel glaucoma shunt
May 7th 2024In a presentation at the Association for Research in Vision and Ophthalmology 2024 annual meeting in Seattle, researchers detailed a novel shunt, which could potentially improve postoperative IOP control and lower the risk of vision-threatening issues.
Read More
ARVO 2024: Researchers drive innovation in retinal research
May 6th 2024A quartet of studies presented at the Association for Research in Vision and Ophthalmology’s 2024 Annual Meeting addressed diverse retina-related challenges and unveiled findings with the potential to revolutionize vision science.
Read More
ARVO 2024: Study validates ChatGPT 4.0 as potential uveitis patient resource
May 5th 2024In a presentation at the Association for Research in Vision and Ophthalmology’s 2024 Annual Meeting in Seattle, Washington, researchers used Google’s recommended top 8 uveitis patient educational websites in the study to determine whether ChatGPT 4.0 could be used as a uveitis patient online resource.
Read More
ARVO 2024: Deep learning model for GA segmentation, adaptable to SS-OCT and SD-OCT data
May 5th 2024At this year's ARVO meeting, Qinqin Zhang, PhD, presented a poster titled "A unified deep learning model for geographic atrophy segmentation: Adaptable to SS-OCT and SD-OCT data with multiple scan patterns." At the conference she gave Ophthalmology Times an overview.
Read More
ARVO 2024: 36-month data from the GALE study of pegcetacoplan
May 5th 2024At this year's ARVO meeting, Ash Abbey, MD, Director of clinical research at Texas Retina Associates, presented 36-month data from the GALE study of pegcetacoplan for the treatment of dry age-related macular degeneration specifically geographic atrophy.
Read More